Efficacy, Tolerability and Adverse Events of Single-Shot Intra-Articular Hyaluronic Acid Injection in Knee Osteoarthritis

Shahid Hussain, M.S.,¹ Hamid Rather, M.D.,² Asif Qayoom, D.T.³

¹ Senior Resident, ² Assistant Professor

Department of Physical Medicine & Rehabilitation,

Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir

³ Senior Resident, Urgent Care Hospital, New Delhi, India.

ABSTRACT

Objective: The clinical experience with single intra-articular hyaluronic acid injection in knee OA is limited. The aim was to assess the therapeutic efficacy, tolerability and adverse events of single-shot intra-articular hyaluronic acid injection in knee OA.

Method: Between February 2008 and December 2010, forty eight (48) patients (Males=21, Females=27) with OA knees were enrolled in this prospective study. These patients had failed to respond adequately to conservative treatment including analgesics and rehabilitative modalities. The inclusion criteria were (1) Resting visual analog scale pain of >50 mm and (2) Radiographic evidence for osteoarthritis and at least one of the following three characteristics; Age ≥50yrs, Morning stiffness ≤ 30 min in duration and coarse crepitus on motion (as per American College of Rheumatology guidelines 1986). Functional scoring as per WOMAC and VAS for pain at rest and during walking was documented. Patient satisfaction was documented as per Linkert scale. Patients received a single injection of Synvisc-One (consisting of 6 ml hylan G-F 20). The patients were reviewed at 1 month, 3 months and 6 months post- injection with final analysis at 1 year. Use of only paracetamol, when required was allowed for concomitant analgesia.

Results: The mean age of the patients was 65 ± 5 years; mean duration of symptoms 5.4 ± 1.5 years and mean body mass index (BMI) 29.1 kg/m². Bilateral knees were involved in 69% of patients. Knee swelling and effusion was present in 70% and 31.5 % patients, respectively. All the patients were available at final follow-up. The resting and walking VAS pain significantly improved from baseline after the injection (45 from 70 and 50 from 82, respectively). There was significant improvement of pain and disability based on the WOMAC scores. Adverse events were recorded and included local pain and swelling, mild redness, and/or effusion in the knee. Based on "Knee Society Score" the overall efficacy was judged as excellent in 55%, satisfactory in 43%, and poor in 2 %. The beneficial effects stayed till 6 months but returned to baseline at last follow up at 1 year.

Conclusions: This study confirmed the therapeutic efficacy and safety of single-shot intra-articular injection of hyaluronic acid for the treatment of osteoarthritis of the knee. The pain relief and functional improvement lasts for up to 6 months. The procedure is tolerated well and associated with very few local adverse events. The need for concomitant analgesia is reduced. JMS 2015; 18(2):128-133

Key Words: Hyaluronic Acid, Knee Osteoarthritis, Visco-supplementation,

INTRODUCTION

Osteoarthritis is the most common chronic joint disorder in the elderly mostly affecting the weight bearing joints of the lower limbs particularly the knees ^[1]. It is characterized by progressive deterioration and loss of articular cartilage and by reactive new bone formation at the joint margins ^[2]. Clinical manifestations include slowly developing joint pain, stiffness, and joint enlargement with limitations of motion.

Knee osteoarthritis results from mechanical and idiopathic

factors that alter the balance between degradation and synthesis of HA in synovial fluid and articular cartilage and subchondral bone.

There are several options for treating osteoarthritis of the knee including conservative (analgesics, physiotherapy/ physical modalities, weight-relieving braces, intra-articular injections) and surgical (osteotomy, arthroplasty) treatment. First proposed by Balazs in 1993 visco-supplementation with intra- articular Hyaluronic acid (HA) injections has emerged as a viable treatment modality for nonoperative care of symptomatic osteoarthritis ^{[2][3]}.

Hyaluronic acid (HA) is a linear, long-chain, unbranched, hydrophilic, high molecular weight muco-polysaccharide forming a critical constituent component of the synovial

Correspondence

Dr. Shahid Hussain, MS

Senior Resident, Department of Physical Medicine & Rehabilitation, SKIMS, Srinagar

Email : drshahid2006@gmail.com

fluid and of cartilage. It is an important contributor to maintain joint homeostasis^[4]. In patients with osteoarthritis, synovial hyaluronic acid is depolymerized and cleared at higher rates than in normal individuals^[2], leading to deterioration of joint cartilage and synovial fluid characteristics etc. and manifesting clinically as pain and loss of function. Specially, there is a decrease in concentration and molecular weight of HA on OA^{[5][6]}. Hence, intraarticular viscosupplementation with HA may restore normal biochemical properties/characteristics in various joint structures, resulting in improved pain control and function^[7].

The exact mechanism by which intra-articular HA or hylans act is currently unknown. Studies have shown the direct analgesic effect of hyaluronic acid in a rat model^[8]. The authors proposed that hyaluronic acid modulates pain by directly inhibiting nociceptors or indirectly binding substance P, which is involved in pain signals. HA blocks the loss of prostaglandins from the cartilage matrix into the synovial fluid, maintaining the normal cartilage structure^[3]. Exogenous HA may facilitate chondrocyte proliferation and de novo synovial synthesis of HAs^{[9][10]}. Relief of knee pain from OA with HA in clinical studies may be due to the effects of HA on nerve impulses and nerve sensitivity^[11] and suppression of inflammatory responses to interleukin-1^{[12][13]}. HA cushions and adds flexibility to cartilage, thus making it resilient to compression.

Presently, HA is indicated for patients with knee OA who fail to respond to conservative measures like physical therapy and pharmacological agents including NSAIDS and interleukin-1 inhibitors etc^[14]. This is corroborated with clinical trials comparing HA and placebo, where in pain relief was significant with HA. Amelioration of pain is comparable with NSAIDS and even superior to intra articular corticosteroid^[17], lasts longer but takes more time to take effect. This latter finding may be especially advantageous in patients in whom typical pain killers are contraindicated or in those who have experienced either a lack of efficacy or other adverse events (patients with peptic ulcer or history of gastro-intestinal bleed).

Given the chronic nature of osteoarthritis, the potential utility of HA is currently limited by the paucity of data concerning not only the effectiveness in the short term^[18] but the effectiveness of long-term multiple courses of

intraarticular HA therapy. The literature on single shot HA injections is even sparser. The purpose of this study was to evaluate both clinical and functional outcomes, patient satisfaction, adverse events and need for concomitant analgesia for knee osteoarthritis after single shot HA injection.

METHODS

Subjects

This single-center prospective clinical trial was approved by the Institute ethical committee. Forty-eight (48) patients were enrolled between Feb 2008 and Dec 2010 (Table 1). All patients had symptomatic knee pain at the tibiofemoral joint and radiographic evidence of osteoarthritis (loss of cartilage thickness, osteophyte formation, subchondral sclerosis, or cysts)^[20]. All patients had received conservative treatment for knee pain in the form of NSAIDS, interleukin-1 inhibitors and physical therapy (ultrasound therapy, short-wave diathermy) with unsatisfactory results.

Table 1:- Patient Demographics

Parameter / Category	Number & Percentage
Total number of Patients	48
Sex	
Female, n (%)	27 (56.2%)
Males, n (%)	21 (43.7%)
Age	
Mean (SD)	65 (±5)
Range	55 to 70
Body Mass Index (kg/m²)	
Mean (SD)	29.1 (4.8)
Knee OA Grading as per Kellgren-Lawrence Classification	
Grade I	0
Grade II	30 (62.5%)
Grade III	18 (37.5%)
Grade IV	0

The patients with unilateral osteoarthritis knee were observed after a single shot intraarticular HA injection with synvisc-One. Although some patients (n=22, 45.8%) had osteoarthritis in the contralateral knee, only the painful and functionally limiting knee was studied. At entry, the affected knee had radiographic evidence of grade 2-3 osteoarthritis^[21]. Patients with grade 4 arthritis and those who had received previous intraarticular HA or glucocorticoid injection were excluded. Patients with inflammatory joint disease, crystal arthropathy, suspicion of infection in or around the affected knee, history of arthroplasty and coagulopathy were also excluded.

Assessment

Patient details and demographic data were documented (age, sex, body mass index, comorbidities, and concomitant medications). The WOMAC^[22] and VAS pain scores were noted. The WOMAC scores range from 0 (best score) to 96 (worst score) based on the three subdomains of pain, stiffness, and difficulty in performing daily activities. The visual analog scale (VAS) ranged from 0 to 100 mm, with lower numbers representing less pain and higher numbers representing more pain. The VAS and WOMAC was used as a self-administered questionnaire in accordance with the developers' instructions^[22]. Patient satisfaction was determined as per Linkert scale^[23] (Figure 1).

Figure 1 : Patient satisfaction at 6 months after hyaluronic acid injection

Intervention

Synvisc-One is supplied as 6ml syringe containing hylan G-F 20 and was purchased by patients from market. Synvisc-One was administered as a single shot injection as per manufacturer's instructions. Under aseptic precautions, the injections were performed via supero- lateral approach with a 22-gauge needle in minor OT. Patients were instructed to refrain from strenuous activity for a day following the intra-articular injections. Synovial fluid analysis was done in 15

Patients.

Patients were instructed to wait a full month following the injection of synvisc-One in order to let the product sufficient time to take effect. Patients were then followed-up at 1, 3 and 6 months with final follow up at 1 year.

RESULTS

Subject Characteristics

Forty-eight (48) patients were recruited for the study over a period of 2 years. Study population baseline demographics are given in Table1. No patient was lost to follow up. Majority of the patients were females (56.2%). 30 patients (62.5%) described one or more comorbid condition at baseline including controlled hypertension, hypothyroidism, diabetes mellitus and acid dyspepsia etc. 80% patients had used NSAIDS, 50% had used diacerin while 35% had received physical modality at some point of time.

Outcome

- A. Evaluation of visual analog pain scale (VAS).
 1. VAS at rest: Visual analog pain scale (VAS) revealed an average score of 70 pre-injection at rest. From this base line, the value dropped to 45
 2. VAS after walking: Walking 30 m revealed an average pain score of 82 pre-injection that dropped to 50.
- B. The WOMAC scores improved with a median decrease from 60 to 44 points.

At 6 months, 79.1 % patients (38) improved with visco-supplementation while 9 (18.75%) remained the same.

One patient (2%) went onto develop septic arthritis managed with intravenous antibiotics and arthrotomy and constituted the poor result in our study. The scores however returned to baseline at the end of 1 year.

- C. Secondary outcome measures included patient satisfaction as per Linkert scale^[23] and frequency of local adverse events (effusions or flares) in injected knees (Figure-2). (79.1%) patient satisfaction with the HA was significant. The patient satisfaction remained so at 1 year also with patients quoting good symptomatic relief with HA injection even though VAS and WOMAC scores indicating otherwise. There were no systemic adverse events reported. Local adverse events including pain and swelling at injection site were observed in injections.

Figure 2 : Adverse events of single-shot hyaluronic acid injection (Note that some patients had more than 1 adverse event while some had none)

Figure 3 : Change in VAS score

DISCUSSION

Osteoarthritis is the most common form of joint disorder in the elderly and a major source of disability ^[1]. The prevalence continues to increase as the older adult and obese populations grow ^{[14][15]}. More than 50% of patients older than 65 years have radiographic changes in the knee that indicates arthritis. It is characterized by activity related pain and troublesome stiffness. Radiological analysis often reveals progressive joint space narrowing, osteophyte formation, bony enlargement and in advanced cases, misalignment of anatomical/ mechanical axis. The etiology is multifactorial with genetic and environmental factors playing important roles. Advancing age and obesity are important predisposing risk factors for primary osteoarthritis. Weight bearing joints like knee, hip, and ankle are commonly involved. In the knee, pain is usually the presenting symptom followed by progressive loss of motion, joint tenderness, effusion and stiffness, and in the later stages, joint deformity. OA knees is often bilateral though symptoms appear in one joint initially.

Traditional non-operative treatment of osteoarthritis includes activity modification, weight loss, rehabilitative exercise, non-steroidal anti-inflammatory medications

(NSAIDs) and intra-articular injections. Surgical treatment, in the form of osteotomy and arthroplasty of the hip and knee is effective, but not indicated for early stages of the disease in all patients. The enormous costs involved and relevance of such procedures in third world setting as ours is debatable.

The first line treatment usually is begun with acetaminophen and NSAIDs, but the treatment is associated with significant morbidity to the gastrointestinal system and renal function^[24]. Interleukin-1 inhibitors are widely used but often associated with troublesome diarrhea^[25]. Intra articular corticosteroid injections for the treatment of osteoarthritic knees are well documented. The symptom relief is prompt but short-lived. Some studies suggest that intra articular corticosteroid injections result in severe deleterious effects, both mechanical and physiological, on the joint and articular cartilage^[26]. Corticosteroid injections can cause skin depigmentation/ atrophy, ligament and tendon rupture and dreaded complication of sepsis. At higher doses, which occur when treating multiple joints, the corticosteroids can inhibit the hypothalamicpituitaryadrenal axis^[27].

Visco-supplementation with HA has gained popularity as a modality for the treatment of osteoarthritis of the knee. These injections provide a combination of viscoelastic properties with associated anti-inflammatory, anabolic, and chondro-protective effects^[28] protecting the joint from compressive and shear forces. The content of synovial fluid, in the presence of osteoarthritis, has a decreased concentration and molecular weight of hyaluronic acid. The rationale for the intraarticular injection of hyaluronic acid is to restore the viscoelasticity of synovial fluid by providing exogenous HA thus helping to augment the flow of synovial fluid, normalize the synthesis and inhibit the degradation of endogenous hyaluronic acid, and relieve joint pain^{[15][29]}. Hyaluronic acid also has several anti- inflammatory effects by inhibiting phagocytosis and adherence of leukocytes. It reduces the levels of inflammatory mediators such as prostaglandin and cyclic adenosine monophosphate. Hyaluronic acid also reduces the release of arachidonic acid from synovial fibroblasts^[27]. The properties of biocompatibility and a prolonged half-life within the synovium are added advantages^[28].

The literature supports the use and efficacy of HA even though AAOS hasn't recommended for or against it. Many

randomized controlled studies have demonstrated a longer-term effect in pain control with HA injections compared with corticosteroids^[30] and placebo^{[31][32]}. Hyaluronic acid has approximately a 1% incidence of side effects per injection. The most common side effects are local reactions of the knee such as swelling, pain, and increased warmth. This type of reaction typically lasts for 1 to 2 days^[7]. With proper patient selection and injection technique, these injections are a viable treatment option for patients with early symptomatic knee OA. The group receiving the hyaluronic acid also had a significantly reduced need for treatment at 1 year^[32].

CONCLUSION

The results of this study show that a single intraarticular injection of hyaluronic acid has a significant effect on functional outcome and reduction of osteoarthritic knee pain. The duration of symptom relief for upto 6 months suggests a possible disease modifying effect of HA in knee osteoarthritis. Patient selection is important to achieve satisfactory results. The response to injection in early OA (Grade 2) is significantly better than in advanced arthritis. Advancing age and obesity seems to be unfavorable variables for symptomatic improvement. The procedure is associated with few local adverse events and decreases the need for concomitant analgesia/ therapeutic modalities. Activity related pain seems to respond better to HA injection which is similar to previous studies^[33]. The need for long-term study cannot be over emphasized.

Even though the literature is replete with data on multiple intra- articular hyaluronic acid in knee osteoarthritis, knowledge on single-shot injections is sparse. When compared with these studies, single-shot hyaluronic acid injections seem equally effective. The lesser hospital visits and procedures is another advantage.

REFERENCES

1. Dieppe P: Osteoarthritis. *Acta Orthop Scand Suppl* 1998;281:2-5
2. Balasz EA, Denlinge SL: Viscosupplementation: A new concept in the treatment of osteoarthritis. *J Rheumatol* 1993;20(sup 39):3-9
3. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 Update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. *Arthritis Rheum* 2000 ;43: 1905-15
4. Laurent TC, Fraser JR. Hyaluronan. *FASEB J*. 1992;6:2397-404
5. Balazs E: The physical properties of synovial fluid and the specific role of hyaluronic acid. In *Disorders of the Knee*. Edited by Helfet AJ. Philadelphia: J B Lippincott; 1982:61- 74.
6. Belcher C, Yaqub R, Fawthrop F, Bayliss M, Doherty M: Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees. *Ann Rheum Dis* 1997, 56:299-307.
7. Rydell N, Balazs EA. Effect of intra- articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. *Clin Orthop*. 1971;80:25-32.
8. Ghosh P. The role of hyaluronic acid (hyaluronan) in health and disease: interactions with cells, cartilage, and components of synovial fluid. *Clin Exp Rheumatol* 1994;12:75-82.
9. Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. *Rheumatol Int* 1987;7:113-22.
10. Bagga H, Burkhardt D, Sambrook P, March L. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. *J Rheumatol* 2006;33:946-50.
11. Begg C, Cho M, Eastwood S. et al: Improving the quality of reporting clinical trials: The CONSORT statement. *JAMA* 1996;276:637-9
12. Yasui T, Akatsuka M, Tobetto K, Hayaishi M, Ando T. The effect of hyaluronan on interleukin-1 -induced prostaglandin E2 production in human osteoarthritic synovial cells. *Agents Actions* 1992;37:155-6.
13. Monfort J, Nacher M, Montell E, Vila J, Verges J, Benito P. Chondroitin sulfate and hyaluronic acid (500-730 kda) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes. *Drugs Exp Clin Res* 2005;31:716.
14. Kim RH, Springer BD, Douglas DA. Knee reconstruction and replacement. In: Flynn F, ed. *Orthopaedic Knowledge Update*. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2011:469-475.
15. Arden N, Nevitt MC. Osteoarthritis: epidemiology.

Best Pract Res Clin Rheumatol. 2006;20(1):3-25.

16. Adams ME, Atkinson MH, Lussier AJ, et al: The role of visco-supplementation with hylan GF-20 (Synvisc) in the treatment of osteoarthritis of the knee: A Canadian multi-center trial comparing Hylan GF-20 alone, hylan GF-20 with non-steroidal anti-inflammatory drugs (NSAIDS) and NSAIDS alone. *Osteoarthritis Cartilage* 1995;3:213-26
17. Mamlin LA, Melfi CA, Parchman ML, et al: Management of osteoarthritis of the knee by primary care physicians. *Arch Fam Med* 1998;7:563-7
18. Lo GH, LaValley M, McAlindon T, et al: intra-articular hyaluronic acid in the treatment of knee osteoarthritis: A meta-analysis. *JAMA* 2003;290:3115-21
19. Lussier A, Cividino AA, McFarlane CA, et al: visco-supplementation with hylan for treatment of knee osteoarthritis: Findings from clinical practice in Canada. *J Rheumatol* 1996;23:1579-85
20. R. ALTMAN et al. Development of criteria for the classification and reporting of osteoarthritis Classification of Osteoarthritis of the Knee; *Arthritis and Rheumatism*, Vol. 29, No. 8 (August 1986)
21. Kellgren JH, Jeffrey MR, Ball J. The epidemiology of chronic rheumatism. *Atlas of standard radiographs of arthritis*. Oxford: Blackwell Scientific Publications; 1963.
22. Bellamy N. WOMAC osteoarthritis index users guide. Queensland, Australia: University of Queensland; 2000. p 1-43.
23. Linkert, Rensis (1932). "A Technique for the Measurement of Attitudes". *Archives of Psychology* 140: 155.
24. Fries JF. The epidemiology of NSAID gastropathy: the ARAMIS experience. *J Clin Rheumatol*. 1998;4(5 suppl):s11-s16.
25. Bartels E.M., Bliddal H., Schøndorff P.K., Altman R.D., Zhang W., Christensen R.; Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta- analysis of randomized placebo- controlled trials; *Osteoarthritis and Cartilage* Volume 18, Issue 3 , Pages 289-296, March 2010
26. Ross A. Hauser. The Deterioration of Articular Cartilage in Osteoarthritis by Corticosteroid Injections. *Journal of Prolotherapy* | Volume 1, Issue 2 | May 2009
27. Jason C. Snibbe, Ralph A. Gambardella; Use of Injections for Osteoarthritis in Joints and Sports Activity. *Clin Sports Med* 24 (2005) 83-91
28. Watterson JR, Esdaile JM. Viscosupplementation: therapeutic mechanisms and clinical potential in osteoarthritis of the knee. *J Am Acad Orthop Surg*. 2000;8(5):277-284.
29. Lee S, Park D, Chmell SJ. Viscosupplementation with hylan G-F
30. (Synvisc): pain and mobility observations from 74 consecutive patients. *J Knee Surg* 2004;17(2):73-7.
31. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. *Cochrane Database Syst Rev*. 2006;19(2):CD005321.
32. Dixon AS, Jacoby RK, Berry H, Hamilton EBD. Clinical trial of intra- articular injection of sodium hyaluronate in patients with osteoarthritis of the knee. *Curr Med Res Opin* 1988;11: 205-13.
33. Dougados M, Nguyen M, Lestrat V, Amor B. High molecular weight sodium hyaluronate (hyalectin) in osteoarthritis of the knee: A 1 year placebo-controlled trial. *Osteoarthritis Cartilage* 1993;1:97-103.
34. Petrella R J, DiSilvestro I MD, Hildebrand C: Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee. *Arch Intern Med* 2002;162:292-8